Inicio・Lista de Acciones・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Cerrado

SectorSanidad

13.14 -2.45

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.92

Máximo

13.45

Métricas clave
By Trading Economics
Ingresos	-1.2M -13M
Ventas	-2.8M 14M
BPA	-0.67
Margen de beneficios	-76.292
Empleados	120
EBITDA	-30M -39M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+48.81% upside

Dividendos
By Acuity
Próximas Ganancias	13 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-22M 400M
Apertura anterior	15.59
Cierre anterior	13.14

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

317 / 340 Clasificación en Healthcare

ENANTA PHARMACEUTICALS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 20:06 UTC

Enanta Pharmaceuticals is trading lower amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13 ago 2026, 19:36 UTC

Enanta Pharmaceuticals Inc is trading higher, remaining above its 20-day moving average, despite no specific company news identified for the price movement.

11 ago 2026, 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, reflecting broader market declines. The stock reached a session low earlier but has since recovered slightly.

5 ago 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower, reflecting broader market sentiment amid disappointing ADP employment data showing a rise of only 44,000 jobs in July.

4 ago 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are higher, buoyed by a decline in crude oil prices that eases inflation concerns. No specific company news was identified.

3 ago 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 jul 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 jul 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 jul 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 jul 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 jul 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Comparación entre iguales

Cambio de precio

ENANTA PHARMACEUTICALS INC previsión

Precio Objetivo

By TipRanks

48.81% repunte

Estimación a 12 Meses

Media 20 USD 48.81%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Sentimiento

By Acuity

317 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.